key: cord-0944986-f5mcgoes
authors: Ozkan, Seda; Tutar, Onur; Akdeniz, Yonca Senem; Cakmak, Fatih; Ipekci, Afsin; Biberoglu, Serap
title: Chest computed tomography findings of eight patients with covid-19 diagnosis: case series
date: 2021-01-19
journal: Acta Biomed
DOI: 10.23750/abm.v91i4.9722
sha: 497a5793ad5bd1c4af623cbb73190a9f27af7177
doc_id: 944986
cord_uid: f5mcgoes

COVID-19 is an infectious disease caused by the virus named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and declared a pandemic on March 11, 2020, by the world health organization. In Turkey, the first cases began to appear on March 11, 2020. After the cases in China, the appearance of ground glass with or without consolidation in the posterior and periphery of the bilateral lung is determined as the main finding of COVID-19. In this article, we wanted to share the tomography findings of eight patients who were diagnosed with COVID-19 in our emergency department and who had lung involvement. (www.actabiomedica.it)

COVID-19 is an infectious disease caused by the virus named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and declared a pandemic on March 11, 2020, by the world health organization. In Turkey, the first cases began to appear on March 11, 2020. The number of patients diagnosed with COVID-19 in our country and all over the world is increasing day by day.

The clinical spectrum of COVID-19 infection is broad. The cases can be seen as asymptomatic, mild upper respiratory disease, mild pneumonia, severe pneumonia, and respiratory failure (1) . SARS-CoV-2 infects respiratory epithelial cells as a result of the interaction of the S protein on its own with the cell angiotensin-converting enzyme 2 receptor (1).

In the diagnosis of COVID-19, real-time reverse transcription-polymerase chain reaction (RT-PCR) of viral nucleic acid is accepted as the reference standard test. However, recent studies have addressed the importance of chest computed tomography (CT) examination in COVID-19 patients with false-negative RT-PCR results (2) . The sensitivity of computed tomography has been reported to be 98% (2) .

In the patient data in China, where the disease was first seen, most patients had bilateral lung involvement. Lung lesions were widely distributed posteriorly, peripherally, and subpleurally. Bilateral widespread ground glass appearance with bilateral consolidation and without consolidation is considered the main finding of COVID-19 (2, 3, 4, 5) .

In our country, COVID-19 cases were seen later than in other countries. In this article, we wanted to share the tomography findings of our first patients who were diagnosed with COVID-19 in our emergency department and who had lung involvement.

A forty-one-year-old male patient was admitted to the emergency department with complaints of fever, cough, and shortness of breath for five days. The patient had no comorbidity and contact history. RT-PCR test was positive. The laboratory values of the patient at the time of admission were as follows: White Blood Count (WBC) 10100 µ / L, Lymphocyte 1400 µ / L, C-reactive protein (CRP) 49.66 mg / L and lactate dehydrogenase (LDH) 176 IU / L. In the tomography of the patient; There were extensive areas of diffuse ground-glass opacities (GGO) accompanied by diffuse placement, with both lungs apparent in the subpleural areas (Fig 1) . In the treatment, the patient was given hydroxychloroquine (2x400 mg / first day, 2x200 mg / 4 days), azithromycin ( 2x250 mg/ first day, 1x250 mg / 4 days), oseltamivir ( 2x75 mg / 5 days). The patient was admitted to the intensive care unit after the oxygen saturations decreased four days later and connected to the ventilator. In intensive care, the patient received treatment with Favipiravir (2x1200 mg / 5 days). The patient was treated in the hospital for 15 days, two days in the intensive care unit, and then discharged.

A sixty-four-year-old male patient was admitted to the emergency department with complaints of fever and cough for one day. He had hypertension. The patient's wife was hospitalized with the diagnosis of COVID-19. In the laboratory values of the patient; WBC was 8600 µ / L, Lymphocyte 1900 µ / L, CRP 65.28 mg / and LDH 416 IU / L. Lung tomography showed diffuse ground-glass densities with diffuse location, more prominent in both lung lower lobes and peripheral areas (Fig 2) . In the treatment, the patient was given hydroxychloroquine (2x400 mg / first day, 2x200 mg / 4 days), azithromycin (2x250 mg / first day, 1x250 mg / 4 days), oseltamivir (2x75 mg / 5 days). No additional treatment was given. The patient was discharged seven days later.

A fifty-six-year-old male patient had complaints of cough, headache, and myalgia for two days. The patient had no additional diseases. The patient returned from Germany a week ago. The patient had no fever. The patient's laboratory values were as follows: WBC 7900 µ / L, Lymphocyte 600 µ / L, CRP 196 mg / L and LDH 396 IU / L. Tomography showed bilateral peripheral ground-glass opacities and consolidations, more prominent in the upper-lower lobes (Fig 3) . Hydroxychloroquine (2x400 mg / first day, 2x200 mg / 4 days), azithromycin (2x250 mg/ first day, 1x250 mg / 4 days), oseltamivir (2x75 mg / 5 days) were given in the treatment. The patient was discharged nine days later. 

Fifty-seven-year-old male patient admitted to the emergency department with the complaint of fever, cough, and shortness of breath for four days. The patient applied to another hospital six days ago, and the RT-PCR test was performed there. Hydroxychloroquine and oseltamivir were started because their tomography was compatible with SARS-CoV-2. When the patient was under follow-up at home, when the dyspnea progressed, he applied to our emergency room. He had no comorbidity. The patient's RT-PCR test was positive. In tomography; In both lung parenchyma, there were areas and consolidations with more common ground-glass density in the upper lobes (Fig 4) . The laboratory values of the patient were as follows; WBC 25.000 µ / TL), Lymphocyte 800 µ / L, CRP 350.71 mg / L, LDH 409 IU / L and Ferritin 669 ng / mL. The patient was hospitalized in the intensive care unit. Favipiravir ( 2x1600 mg first day, 2x600 mg / 7 days), hydroxychloroquine (2x200 mg / 5 days) and Tocilizumab (1x400 mg / day, one time) were started in the patient, whose oxygen saturation was 92%. Seven days later, the patient was removed from the intensive care unit and transferred to the regular clinic. The patient was discharged on the 14th day of hospitalization.

Sixty-four-year-old male patient admitted to the emergency department with the complaint of back pain for five days. The patient had no fever and cough complaints. A kidney was removed due to malignancy. He had contact with tourists from abroad. Tomography findings: The bilateral lower lobes have more prominent peripheral ground-glass opacities and consolidations (Fig 5) . The laboratory values of the patient were as follows; WBC 4.500 µ / TL), Lymphocyte 700 µ / L, CRP 38.9 mg / L, and LDH 225 IU / L. The patient had a fever on the second day of hospitalization. The COVID-19 PCR test was positive. The patient was given hydroxychloroquine (2x400 mg / first day, 2x200 mg / 4 days), azithromycin (2x250 mg / first day, 1x250 mg / 4 days), oseltamivir (2x75 mg / 5 days). On the seventh day of hospitalization, the patient was started on favipiravir (2x1600 mg / first day, 2x600 mg / 4 days) and vitamin C (1x1 g). The patient was discharged from the hospital 14 days later.

Sixty-five-year-old male patient admitted with the complaint of cough, shortness of breath, and weakness for six days. The patient came from Mecca a week ago. There is no history of chronic disease. The patient had no fever. The patient's WBC (10.4 10x3µ / L), CRP (261 mg / L) and LDH (301 IU / L) levels were high. The lymphocyte value was 600 µ / L. In the patient's lung tomography; there were consolidations, and paving stone views bilaterally in the lower lobes with peripheral ground-glass opacities (Fig 6) . RT-PCR test was positive. Hydroxychloroquine (f2x400 mg/first day dose, 2x200 mg / 4 days), azithromycin (2x250 mg/ first day, 1x250 mg / 4 days), oseltamivir (2x75 mg / 5 days) were given in the treatment. On the third day of his admission, Tocilizumab (1x400 mg/ day, one time) was given when ferritin level increased (1745 ng / mL), and Favipiravir (2x1600 mg / first day, 2x600 mg / 4 days) was given when hypoxia developed. On the fourth day of hospitalization, D-dimer level (58.28 mg / L) increased, and Enoxaparin was given to the patient. The patient was discharged 11 days later.

A forty-six-year-old male patient admitted to the emergency room with a complaint of cough and fever for three days. The patient has uncontrolled diabetes mellitus. RT-PCR test was positive. He works as a security guard in the hospital. Laboratory values of the patient at admission were as follows: WBC 9.400 µ / L), Lymphocyte 1700 µ / L, CRP 135.97 mg / L, LDH 302 IU / L. In the CT; in both lung parenchyma, there are patchy areas, and peripheral groundglass opacities in the upper and lower lobes (Fig 7) . The patient was started on hydroxychloroquine (2x400 mg / first day, 2x200 mg / 4 days), azithromycin (2x250 mg/ first day, 1x250 mg / 4 days), oseltamivir (2x75 mg / 5 days). On the fifth day of hospitalization, Favipiravir was started when hypoxia appeared, and on the sixth day, Tocilizumab was started when Ferritin level increased to 2205 ng / mL. The patient was discharged after 17 days when the RT-PCR test became negative.

Fifty-year-old male patient admitted to the emergency department with the complaint of cough and shortness of breath for five days. The patient had no fever, comorbidity, and a history of contact. Laboratory values of the patient at admission were as follows:

WBC 5800 µ / L, Lymphocyte 1500 µ / L, CRP 5.84 mg / L, LDH 306 IU / L. CT scan showed bilateral peripheral ground-glass opacities, paving stone views, areas with reverse halo sign appearance, and consolidations especially in lower lobes (Fig 8) . In the treatment, hydroxychloroquine (2x400 mg / first day, 2x200 mg / 4 days), azithromycin ( 2x250 mg/ first day, 1x250 mg / 4 days), oseltamivir (2x75 mg / 5 days) were given. RT-PCR test was positive. The patient was discharged five days later.

In the patient data in China, where the disease was first seen, most patients had bilateral lung involvement. Zhou et al. reported that 191 patients had consolidation in 59%, ground-glass opacity in 71%, and bilateral infiltration in 75% (1).

Heshoui et al. reported that the dominant lesion was ground-glass opacity with indeterminate margins, air bronchograms, smooth or irregular interlobular or septal thickening, and thickening of the adjacent pleura (3). In a study conducted in Korea, COVID-19 pneumonia generally manifested as pure ground-glass opacity to mixed ground-glass opacity and consolidative lesions in the bilateral peripheral posterior lungs (4) . The shape of the injuries is typically ill-defined and patched or nodular. Irregular-confluent lesions are primarily distributed throughout the pleura, while nodular lesions are mostly distributed along with the bronchovascular bundles (4).

The study of Xu et al. showed bilateral, multifocal ground-glass opacities, with peripheral distribution in patients with SARS-CoV-2 pneumonia. More than half of the patients had multilobar involvement, and lesions were more common in the lower lobes (6) .

Bilateral diffuse multifocal ground-glass opacities and consolidations were observed as typical tomography findings in our cases. Reticular pattern, air bronchogram, vascular enlargement, pleural thickening, crazy paving pattern, air bubble sign, halo sign were the other tomographic findings that we detected in our cases. Our findings are consistent with previous studies and may be helpful in the early detection of SARS-CoV-2 pneumonia.

As a result, the appearance of ground glass with or without consolidation in the posterior and periphery of the bilateral lung is likely the main finding of COVID-19. RT-PCR results may delay and could be false negative so CT seems to be helpful in the early diagnosis.

Each author declares that he or she has no commercial associations (e.g. consultancies, stock ownership, equity interest, patent/licensing arrangement etc.) that might pose a conflict of interest in connection with the submitted article.

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Chest CT manifestations of new coronavirus disease 2019 (COVID-19): a pictorial review

Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study

Chest Radiographic and CT Findings of the 2019 Novel Coronavirus Disease (COVID-19): Analysis of Nine Patients Treated in Korea

Relation Between Chest CT Findings and Clinical Conditions of Coronavirus Disease (COVID-19) Pneumonia: A Multicenter Study

Imaging and clinical features of patients with 2019 novel coronavirus SARS-CoV-2